N/A N=1,297 School Water Access, Food and Beverage Intake, and Obesity
Obesity
Primary: Number of Participants With Age- and Sex-adjusted BMI% Greater Than or Equal to 85% — 335; 273; 315; 263 Participants — p=0.68
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=178 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
Ulcerative Colitis
Primary: Percentage of Participants in Cohort 1 Achieving Clinical Remission — 26.5; 1.5 Percentage of participants — p=<.0001
N/A N=123 CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
CCM · Cavernoma · Cerebral Cavernous Malformation
Primary: Rate of Recurrent Symptomatic Hemorrhage During the Two Year Follow-up Period in Patients With CASH. — 10; 11 Number of new bleeds
Phase 3 N=393 Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Carcinoma · Limited Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Deterioration in HVLT-R Delayed Recall Score at Six Months (Phase III) — 33; 27 Participants — p=0.28
N/A N=378 Simplifying Survivorship Care Planning
Cancer
Primary: Number of Participants Compliant With Follow-up Care Visits — 47; 53; 44 Participants
Phase 3 N=632 Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Amyloidosis · Amyloid Cardiomyopathy · Transthyretin Amyloidosis
Primary: A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT…
N/A N=20 Compass Device CVC Trial
Blood Pressure
Primary: Operator Satisfaction — 8 score on a scale
N/A N=67 Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: SCD-specific Knowledge — 32.0; 32.0; 33.5; 33 score on a scale
Phase 2 N=76 Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Bladder Cancer
Primary: Clinical Complete Response (CCR) Rate — 43 Percentage of participants
Phase 2 N=132 Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 75% Reduction From Baseline in Psoriasis Area Severity Index (PASI) Score (PASI-75) at Week 16 — 58.3…
N/A N=152 A Therapeutic Workplace to Address Poverty and Substance Use
Substance Use Disorders
Primary: Alcohol Abstinence — 82.8; 60.2 percentage of participants — p=<0.001
Phase 4 N=30 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Actinic Keratosis
Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses
N/A N=217 Electronic Pre-exposure Prophylaxis (PrEP) Initiation and Maintenance Home Care System
Pre-exposure Prophylaxis
Primary: Difference in Tenofovir-diphosphate (TFV-DP) Levels Between Intervention and Control Arms at 6 Months Follow-up — 17; 7 Participants
Phase 4 N=30 Envarsus Neurotoxicity Burden in Liver Transplant Patients
Neurotoxicity · Liver Transplant; Complications
Primary: Change in Neurotoxicity Burden — -5; -4 score on a scale
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001